Efficacy and safety of Avalglucosidase Alfa in participants with late-onset Pompe Disease after 145 weeks' treatment during the COMET trial Schoser, B., Kishnani, P., Kushlaf, H., Ladha, S., Mozaffar, T., Straub, Toscano, A., van der Ploeg, A., Clemens, P., Day, J., Illarioshkin, S., Roberts, M., Attarian, S., Carvalho, G., Erdem-Ozdamar, S., Goker-Alpan, O., Kostera-Pruszczyk, A., Diaz-Manera, J., Dimachkie, M., COMET Investigator Grp PERGAMON-ELSEVIER SCIENCE LTD. 2022

View details for Web of Science ID 000873062200397